PBLS Stock Analysis: Parabilis Medicines, Common | NASDAQ

Biotechnology | NASDAQ, USA | Market Cap: 3.741m USD | Charts, Fundamentals & Technical Analysis

Total Rating 10
Safety 43
Buy Signal 0.37
Biotechnology
Industry Rotation: +30.9
Market Cap: 3.74B
Avg Turnover: 25.0M
Risk 3d forecast
Volatility76.0%
VaR 5th Pctl13.0%
VaR vs Median3.46%
Reward TTM
Sharpe Ratio-0.33
Rel. Str. IBD0
Rel. Str. Peer Group-
Character TTM
Beta
Beta Downside
Hurst Exponent
Drawdowns 3y
Max DD20.85%
CAGR/Max DD-2.16
CAGR/Mean DD-3.93
EPS (Earnings per Share) EPS (Earnings per Share) of PBLS over the last years for every Quarter: "2024-12": null, "2025-03": null, "2025-12": null, "2026-03": null,
Revenue Revenue of PBLS over the last years for every Quarter: 2024-12: 0, 2025-03: 0, 2025-12: 0, 2026-03: 0,
Qual. Beats: 0

Warnings

Negative Equity With Losses: Insolvent Profile
Interest Coverage Ratio Critical
Altman Z'' In Financial Distress Zone

Tailwinds

No distinct edge detected

Seasonality

Not enough history
Description: PBLS Parabilis Medicines, Common
Parabilis Medicines, Inc. operates as a clinical-stage biopharmaceutical company focused on developing helical peptide therapeutics for disease treatment. The company develops stabilized helical peptide therapeutics through its Helicon discovery platform, targeting proteins that are traditionally considered undruggable. Its pipeline includes functional inhibitors of intracellular protein-protein interactions, targeted protein degraders, and targeted radiopharmaceuticals, with a lead clinical program, FOG-001, that acts as a TCF-blocking beta-catenin inhibitor for cancer treatment. The company integrates artificial intelligence and data science into drug discovery, trial design, and clinical strategy optimization. Parabilis Medicines serves clients in the healthcare and life sciences industries, including clinical research organizations and medical professionals involved in oncology and cancer treatment. The company was founded in 2015 and is based in Cambridge, Massachusetts.
Headlines to Watch Out For
Piotroski VR-10 (Strict) 0.5
Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM)
FCF/TA: -0.32 > 0.02 and ΔFCF/TA 37.73 > 1.0
NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev)
CFO/TA -0.32 > 3% & CFO -123.7m > Net Income -145.9m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 6.12 > 1.5 & < 3
Outstanding Shares: last fiscal year (118.1m) vs prev 0.0% < -2%
Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin)
Asset Turnover: 0.0% > 50% (prev 0.0%; Δ 0.0% > 0%)
Interest Coverage Ratio: -99.92 > 6 (EBIT TTM -152.1m / Interest Expense TTM 1.52m)
Altman Z'' -2.23
A: 0.72 (Total Current Assets 332.1m - Total Current Liabilities 54.2m) / Total Assets 384.2m
B: -1.53 (Retained Earnings -586.8m / Total Assets 384.2m)
C: -0.57 (EBIT TTM -152.1m / Avg Total Assets 266.7m)
D: 1.75 (Book Value of Equity 244.2m / Total Liabilities 140.0m)
Altman-Z'' = -2.23 = D
What is the price of PBLS shares?

As of July 08, 2026, the stock is trading at USD 30.35 with a total of 508,611 shares traded. Over the past week, the price has changed by +0.00%, over one month by +0.00%, over three months by +0.00% and over the past year by +0.00%.

Current recommended Stop Loss: 26.60 (which is 12.4% or 1.3 ATR below the current price).

Is PBLS a buy, sell or hold?

Parabilis Medicines, Common has no consensus analysts rating.

Parabilis Medicines, Common (PBLS) - Fundamental Data Overview as of 08 July 2026
Market Cap USD = 3.74b (3.74b USD * 1.0 USD.USD)
Revenue TTM = 0.0 USD
EBIT TTM = -152.1m USD
EBITDA TTM = -149.6m USD
 Long Term Debt = unknown (none)
 Short Term Debt = 9.40m USD (from shortLongTermDebt, last quarter)
Debt = 43.7m USD (Leases only: 43.7m)
Net Debt = -285.3m USD (calculated: Debt 43.7m - CCE 329.0m)
Enterprise Value = 3.46b USD (3.74b + Debt 43.7m - CCE 329.0m)
Interest Coverage Ratio = -99.92 (Ebit TTM -152.1m / Interest Expense TTM 1.52m)
EV/FCF = -27.86x (Enterprise Value 3.46b / FCF TTM -124.0m)
FCF Yield = -3.59% (FCF TTM -124.0m / Enterprise Value 3.46b)
 FCF Margin = unknown (Revenue TTM is 0 or missing)
 Net Margin = unknown
 Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
 Tobins Q-Ratio = 8.99 (Enterprise Value 3.46b / Total Assets 384.2m)
Interest Expense / Debt = 3.48% (Interest Expense 1.52m / Debt 43.7m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -120.1m (EBIT -152.1m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 4.79 (Total Current Assets 332.1m / Total Current Liabilities 69.3m)
Debt / Equity = 0.18 (Debt 43.7m / totalStockholderEquity, last quarter 244.2m)
 Debt / EBITDA = 1.91 (negative EBITDA) (Net Debt -285.3m / EBITDA -149.6m)
 Debt / FCF = 2.30 (negative FCF - burning cash) (Net Debt -285.3m / FCF TTM -124.0m)
 Total Stockholder Equity = -16.5m (last fiscal year from totalStockholderEquity)
RoA = -54.70% (Net Income -145.9m / Total Assets 384.2m)
 RoE = 882.9% (negative equity) (Net Income TTM -145.9m / Total Stockholder Equity -16.5m)
 RoCE = -46.09% (EBIT -152.1m / Capital Employed (Total Assets 384.2m - Current Liab 54.2m))
 RoIC = -36.41% (negative operating profit) (NOPAT -120.1m / Invested Capital 329.9m)
 WACC = 0.03% (E(3.74b)/V(3.78b) * Re(0.0%) + D(43.7m)/V(3.78b) * Rd(3.48%) * (1-Tc(0.21)))
Discount Rate = 5.29% (= Risk Free + ERP)
 [DCF] Fair Price = unknown (Cash Flow -124.0m)
 Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: N/A | # QB: 0